Huntington’s Disease NewsMechanism in Stem Cells May Help Delay Aging-Related DiseasesHuntington’s Disease NewsResearchers have identified a molecular mechanism in stem cells that may delay the onset of aging-related diseases associated with the produc… Continue reading
Business Wire (press release) |
RenovaCare Awarded U.S. Patent For SkinGun™ Device To Spray Stem Cells On To Wounds
Business Wire (press release) NEW YORK & PITTSBURGH–(BUSINESS WIRE)–RenovaCare, Inc., (RCAR), developer of the patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today … |
FierceBiotech |
TiGenix files for $43M IPO to fund stem cell therapy ph3
FierceBiotech TiGenix has taken another step toward its delayed Nasdaq IPO. The stem cell therapy specialist is aiming to net $42.9 million (€39.8 million) through the listing, approximately half of which will go toward a U.S. late-phase trial of Crohn’s disease … |
FierceBiotech |
TiGenix files for $43M IPO to fund stem cell therapy ph3
FierceBiotech TiGenix has taken another step toward its delayed Nasdaq IPO. The stem cell therapy specialist is aiming to net $42.9 million (€39.8 million) through the listing, approximately half of which will go toward a U.S. late-phase trial of Crohn’s disease … |
Herald Sun |
Use keywords to search content on this website
Herald Sun Royal Women’s Hospital researchers are uncovering the role of placental stem cells in ageing and have found that even in as little as four weeks — between 37 weeks to 41 weeks gestation — key ageing markers can double. An early delivery can be fatal … |
The Ledger |
Pro athletes, others try PRP and stem cell injections
The Ledger n iOrthoBiologix, which opened this summer in Ballantyne, was featured in a recent Men’s Health magazine about the benefits of stem cell therapy: “The idea is that you’re giving your own body more healing potential by using your own restorative stem … |
Medscape |
CAR T Cells Motoring to Market — by Next Year?
Medscape Novartis’ product is CTL019, an anti-CD19 CAR T-cell therapy. The product, which is currently named tisagenlecleucel-T, was developed for use in the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL) in pediatric patients. Results … Can CAR–T cancer treatments be fine-tuned to avoid toxic side effects?FierceBiotech CD22-Targeted CAR T-Cell Therapy Active for Relapsed/Refractory ALLCancer Network Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALLOncLive Fred Hutch News Service all 17 news articles » |